关键信息
-
基因名
MUC-1
- 应用
-
别名
MUC-1;Breast carcinoma-associated antigen DF3;Cancer antigen 15-3;CA 15-3;Carcinoma-associated mucin;Episialin;H23AG;Krebs von den Lungen-6;KL-6;PEMT;Peanut-reactive urinary mucin;PUM;Polymorphic epithelial mucin;PEM;Tumor-associated epithelial membrane antigen;EMA;Tumor-associated mucin;CD antigen CD227;MUC1-NT;MUC1-alpha;MUC1-beta;MUC1-CT
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P15941
-
表达区间
890-1158 aa
-
氨基酸序列
STAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDTRPAPGSTAPPAHGVTSAPDNRPALGSTAPPVHNVTSASGSASGSASTLVHNGTSARATTTPASKSTPFSIPSHHSDTPTTLASHSTKTDASSTHHSSVPPLTSSNHSTSPQLSTGVSFFFLSFHISNLQFNSSLEDPSTDYYQELQRDISEMFLQIYKQGGFLGLSNIKFRPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISDVSVSDVPFPFSAQSGAGVPG
-
分子量
27.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
MUC-1, a type of mucin glycoprotein, is primarily expressed on the apical surface of epithelial cells and plays a crucial role in maintaining mucosal barrier function and immune response modulation. Its overexpression is commonly associated with various malignancies, particularly breast and ovarian cancers, making it a significant target for cancer immunotherapy. The study of recombinant MUC-1 proteins has gained momentum in recent years due to their potential use as vaccines and therapeutic agents to elicit specific immune responses against cancer cells. Researchers aim to harness the immunogenic properties of MUC-1 to develop vaccines that can stimulate T-cell responses, enhancing anti-tumor immunity. Moreover, understanding the structure and function of recombinant MUC-1 can provide insights into its interaction with immune cells and its role in tumorigenesis. Various strategies, including gene engineering and recombinant DNA technology, have been employed to produce MUC-1 proteins with different glycosylation patterns, influencing their immunogenicity and stability. Additionally, the development of MUC-1 based nano-carriers for targeted drug delivery is under exploration, aiming to improve therapeutic efficacy while minimizing side effects. Overall, the study of MUC-1 recombinant proteins is pivotal in advancing cancer immunotherapy, paving the way for new treatment modalities that could improve patient outcomes in malignancies characterized by MUC-1 overexpression.
